CCC: Cardiac COVID-19 Health Care Workers

Sponsor
AORTICA Group (Other)
Overall Status
Completed
CT.gov ID
NCT04413071
Collaborator
Salamanca University Hospital (Other), Instituto de Investigación Biomédica de Salamanca (Other)
142
1
18
240.1

Study Details

Study Description

Brief Summary

The study will analyze the prevalence of cardiac involvement of health care workers from the University Hospital of Salamanca (HUSA) who have overcome SARS-CoV-2 infection. Participants will undergo a clinical evaluation, electrocardiogram (EKG), cardiac magnetic resonance (CMR) and blood analysis including NT-proBNP, troponin, cellular and humoral immunity and genetics.

Condition or Disease Intervention/Treatment Phase
  • Other: Passed infection of SARS-CoV-2

Detailed Description

Most people infected with SARS-CoV-2 experience mild, self-limiting symptoms that have been managed in an outpatient setting and therefore have not undergone routine cardiac evaluation with EKG or cardiac imaging test. Similarly, although the emphasis has been placed on evaluating patients with severe respiratory symptoms, most of these patients have also not undergone cardiac imaging tests and; therefore, in both scenarios, possible myocarditis has not routinely evaluated.

The present study is designed to characterize cardiac involvement in individuals who have overcome the SARS-CoV-2 infection.

For that aim, the study is designed as an observational cross-sectional study. The target population are HUSA healthcare workers who have overcome SARS-CoV-2 infection, either symptomatic or asymptomatic, either having required hospital admission or not. Participants will undergo a clinical evaluation, electrocardiogram (EKG), cardiac magnetic resonance (CMR) and blood analysis including NT-proBNP, troponin, cellular and humoral immunity and genetics.

Main objectives of the study are to address the prevalence of myocardial damage suggestive of myocarditis and to address the prevalence of pericarditis in HUSA health care workers; both related to the systemic immune response to SARS-CoV-2 infection. As secondary objectives the study will further address other cardiac affections including: rhythm or conduction disorders, ischemic heart disease, dilatation of the right chambers, valve disease and will analyze the relationship between humoral and cellular immunity and the presence of cardiac involvement, and the genetic susceptibility in the development of cardiac involvement after SARS-CoV-2 infection.

The study will recruit 141 participants: 47 symptomatic hospitalized health care workers, 47 asymptomatic non-hospitalized health care workers, 47 asymptomatic health care workers

Study Design

Study Type:
Observational
Actual Enrollment :
142 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Cardiac Involvement in Coronavirus (SARS-Cov-2) Infected Health Care Workers: The CCC Study
Actual Study Start Date :
May 25, 2020
Actual Primary Completion Date :
Jun 12, 2020
Actual Study Completion Date :
Jun 12, 2020

Arms and Interventions

Arm Intervention/Treatment
Health care workers

Health care workers from the University Hospital of Salamanca who have passed SARS-CoV-2 infection.

Other: Passed infection of SARS-CoV-2
This is an observational design. Participants have passed infection from SARS-CoV-2 and a cardiac assessment is performed.

Outcome Measures

Primary Outcome Measures

  1. Myocarditis [up to 3 months]

    Prevalence of myocardial damage suggestive of myocarditis assessed by cardiac magnetic resonance

  2. Pericarditis [up to 3 months]

    Prevalence of pericarditis assessed by clinical criteria

Secondary Outcome Measures

  1. Atrial fibrillation [up to 3 months]

    Prevalence of atrial fibrillation on EKG

  2. Ischemic heart disease [up to 3 months]

    Prevalence of ischemic heart disease assessed by cardiac magnetic resonance

  3. Dilatation of right heart chambers [up to 3 months]

    Prevalence of dilatation of right heart chambers assessed by cardiac magnetic resonance

  4. Valvular hear disease [up to 3 months]

    Prevalence of valvular heart disease assessed by cardiac magnetic resonance

  5. Rhythm disorders [up to 3 months]

    Prevalence of prolonged QT interval on EKG

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 71 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Have overcome the SARS-CoV-2 infection meeting any of the following criteria (i) positive result on a reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of a specimen collected on a nasopharyngeal swab followed by a second negative RT-PCR and at least 14 days from this negative RT-PCR; (ii) presence of IgM antibodies and negative RT-PCR after the antibody assessment; (iii) presence of neutralizing IgG antibodies and absence of IgM.

  • stable clinical situation, which allows performing a CMR.

  • signature of informed consent.

Exclusion Criteria:
  • Presence of IgM antibodies without negative subsequent RT-PCR.

  • Contraindications to perform RMC: (i) gadolinium allergy, (ii) presence of metallic material in the body, such as plates, screws, incompatible pacemakers, etc. (iii) claustrophobia, (iv) severe kidney failure, (v) severe liver failure, (vi) sickle cell anemia

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital of Salamanca Salamanca Spain 37007

Sponsors and Collaborators

  • AORTICA Group
  • Salamanca University Hospital
  • Instituto de Investigación Biomédica de Salamanca

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Pedro L Sanchez, Director of the Cardiology Department, Professor of Medicine, Salamanca University Hospital
ClinicalTrials.gov Identifier:
NCT04413071
Other Study ID Numbers:
  • CCC_2020
First Posted:
Jun 2, 2020
Last Update Posted:
Jun 16, 2020
Last Verified:
Jun 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 16, 2020